Population PK of Antibiotics, Sedative and Analgesics, and Antiplatelet Drugs During ECMO

Gachon University Gil Medical Center10 enrolled

Overview

The purpose of this study is to optimize the dosage regimen of drugs in patients during during Extracorporeal Membrane Oxygenation (ECMO) by population pharmacokinetic modeling.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Pharmacokinetics Extracorporeal Membrane Oxygenation

Interventions

Residual bloodOTHER

Residual blood samples(1\~2 cc) at each sampling time are collected from all subjects while using ECMO for drug concentration assays(LC-MS/MS etc.).

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who are taking levofloxacin, meropenem, vancomycin, cefepime, midalzolam, dexmedetomidine, propofol, clopidogrel, ticagrelor, or prasugrel while underdoing Extracorporeal Membrane Oxygenation Exclusion Criteria: * Pregnant women * Receiving a therapy that can affect blood concentration due to a drug-drug interaction with levofloxacin, meropenem, vancomycin, cefepime, midalzolam, dexmedetomidine, propofol, clopidogrel, ticagrelor, or prasugrel

Locations (1)

Gacheon University Gil Medical Center

Incheon, South Korea

RECRUITING

Outcomes

Primary Outcomes

Pharmacokinetic parameters

Volume of distribution

Time frame: Day 0 to day 3 during ECMO, Day 0 to day 3 after removing ECMO

Pharmacokinetic parameters

Clearance

Time frame: Day 0 to day 3 during ECMO, Day 0 to day 3 after removing ECMO

Pharmacokinetic parameters

Absorption rate (if oral drugs)

Time frame: Day 0 to day 3 during ECMO, Day 0 to day 3 after removing ECMO

Central Contacts

Jin Wi, Prof

CONTACT

+82 32-460-3663 caesar@gilhospital.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.